Proteome Sciences and Icon Collaborate on Mass Spec Assays for Pharma Biomarker Development
November 19, 2010
Proteome Sciences and Icon Collaborate on Mass Spec Assays for Pharma Biomarker Development
Proteome Sciences will provide Icon's clients with its expertise in single-reaction monitoring mass spectrometry, said a company official. The partners' first joint project is the development of an SRM assay measuring a biomarker for an unnamed drugmaker.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Protein Biomarkers for Alzheimer's Predicted to Represent Cumulative $9B Market Over Next Decade
June 3, 2011 / ProteoMonitor - Proteome Sciences Inks Deal with Eisai for First Commercial Use of Alzheimer's Biomarker Panel
February 4, 2011 / ProteoMonitor - Taking Aim at Clinical Oncology Market, Proteome Sciences Developing SRM-MS Assay for ER Status
July 22, 2011 / ProteoMonitor - Gothenburg Scientists ID Tyr10-Glycosylated A-beta as Potential Alzheimer's Biomarker
July 15, 2011 / ProteoMonitor - New Alzheimer's Guidelines Call for Use of Protein Biomarkers in Clinical Research
April 22, 2011 / ProteoMonitor